Karyopharm commences two KPT-330 phase 1 studies in cancers

NewsGuard 100/100 Score
Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of patients in the first-in-human clinical trials with KPT-330. KPT-330 is the first oral SINE CRM1 antagonist to enter human studies.  SINEs specifically and irreversibly inhibit the nuclear export protein CRM1 (chromosome region maintenance protein 1), also called exportin 1 (XPO1).  CRM1 is the exclusive mediator of nuclear export of p53, p73, pRb, FOXO, p21, p27, BRACA1, the endogenous inhibitor of Nuclear Factor kB (NF-kB) known as IkB, and other tumor suppressor and growth regulatory proteins. Nuclear export of these key proteins leads to their functional inactivation.  Blockade of CRM1 leads to accumulation and activation of tumor suppressor and growth regulatory proteins in the nucleus, leading to potent and selective tumor cell apoptosis while sparing normal cells. 

Patient dosing has been initiated in two phase 1 studies.  The primary endpoints of both studies are to determine the safety and tolerability profile and the maximum tolerated dose of KPT-330 given orally 2-3 times per week. The first study includes patients with advanced solid tumors whose disease has progressed after at least one prior therapy for metastatic disease (NCT01607905).  The second study includes patients with advanced hematologic malignancies including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and Waldenstrom's macroglobulinemia whose disease has relapsed after standard therapies (NCT01607892). Sharon Shacham, PhD, MBA, Karyopharm's Founder, Chief Scientific Officer, and head of research and development commented, "The initiation of these two Phase 1 trials with KPT-330 is a key milestone since the closing of our Series A funding and the initiation of our Company's operations in late 2010.  This is the first oral SINE to ever enter human studies, and we are eager to assess the potential of our drug candidate across a wide variety of cancers."

Source: Karyopharm Therapeutics Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Study highlights an immunological mechanism underlying Long COVID